ESSA Pharma Inc
NASDAQ:EPIX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
ESSA Pharma Inc
NASDAQ:EPIX
|
CA |
|
N
|
NB Bancorp Inc
NASDAQ:NBBK
|
US |
|
Arshiya Ltd
NSE:ARSHIYA
|
IN |
|
Webis Holding PLC
LSE:WEB
|
IM |
|
Biocorp Production SA
PAR:ALCOR
|
FR |
|
V
|
Venator Materials PLC
OTC:VNTRF
|
UK |
|
N
|
ND Rubber PCL
SET:NDR
|
TH |
ESSA Pharma Inc
ESSA Pharma, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 30 full-time employees. The firm is focused on developing therapies for the treatment of prostate cancer. The Company’s lead candidate, EPI-7386 is an oral, small molecule that inhibits the androgen receptor (AR) through a novel mechanism of action (N-terminal domain inhibition). The firm is evaluating EPI-7386 as a monotherapy for the treatment of adult male patients with metastatic castration-resistant prostate cancer (mCRPC) resistant to standard-of-care treatments.
ESSA Pharma, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 30 full-time employees. The firm is focused on developing therapies for the treatment of prostate cancer. The Company’s lead candidate, EPI-7386 is an oral, small molecule that inhibits the androgen receptor (AR) through a novel mechanism of action (N-terminal domain inhibition). The firm is evaluating EPI-7386 as a monotherapy for the treatment of adult male patients with metastatic castration-resistant prostate cancer (mCRPC) resistant to standard-of-care treatments.
